Latest Breaking News On - Lankenau heart institute - Page 1 : vimarsana.com

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

Prominent trialists took issue with the primary endpoint, how it was powered, and what effect COVID-19 and Katsanos played.

Eating Disorders Can Damage the Heart, Experts Say

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Medtronic has positive Evolut TAVR data

Medtronic (NYSE: MDT) today reported two different datasets that support its Evolut transcatheter aortic valve replacement (TAVR) system.

AFib and Stroke Prevention tips from Main Line Health